CR20230456A - Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo - Google Patents

Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo

Info

Publication number
CR20230456A
CR20230456A CR20230456A CR20230456A CR20230456A CR 20230456 A CR20230456 A CR 20230456A CR 20230456 A CR20230456 A CR 20230456A CR 20230456 A CR20230456 A CR 20230456A CR 20230456 A CR20230456 A CR 20230456A
Authority
CR
Costa Rica
Prior art keywords
ganglioside
antigen
binding fragment
monoclonal antibody
methods
Prior art date
Application number
CR20230456A
Other languages
English (en)
Inventor
Alina Konstantinovna Stolyarova
Yulia Sergeevna Chernykh
Dina Khaidarovna Sakharova
Sergei Andreevich Ageev
Valeriia Evgenevna Shigina
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Mariia Anatolevna Grefenshtein
Valery Vladimirovich Solovyev
Diana Aleksandrovna Kondinskaia
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021107773A external-priority patent/RU2796937C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CR20230456A publication Critical patent/CR20230456A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a un anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al GD2 (gangliósido GD2). La invención se refiere además a ácidos nucleicos que codifican dicho anticuerpo, vectores de expresión, células huésped y métodos para producirlos, métodos para producir los anticuerpos según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades o trastornos mediados por GD2, usos de los anticuerpos o composiciones farmacéuticas de los mismos para tratar enfermedades o trastornos mediados por GD2, y usos de los anticuerpos y otros compuestos terapéuticamente activos para tratar enfermedades o trastornos mediados por GD2.<br /> <br />
CR20230456A 2021-03-24 2022-03-24 Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo CR20230456A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021107773A RU2796937C2 (ru) 2021-03-24 Моноклональное антитело или его антигенсвязывающий фрагмент, которое специфически связывается с gd2 (ганглиозид gd2), и его применение
PCT/RU2022/050096 WO2022203552A1 (en) 2021-03-24 2022-03-24 Monoclonal antibody that specifically binds to gd2

Publications (1)

Publication Number Publication Date
CR20230456A true CR20230456A (es) 2023-12-13

Family

ID=83395963

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230456A CR20230456A (es) 2021-03-24 2022-03-24 Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo

Country Status (15)

Country Link
CN (1) CN117677695A (es)
AR (1) AR125219A1 (es)
CL (1) CL2023002843A1 (es)
CO (1) CO2023012549A2 (es)
CR (1) CR20230456A (es)
EC (1) ECSP23072412A (es)
JO (1) JOP20230231A1 (es)
MA (1) MA62715B1 (es)
MX (1) MX2023011246A (es)
PE (1) PE20231854A1 (es)
PY (1) PY2221503A (es)
TW (1) TW202304989A (es)
UY (1) UY39687A (es)
WO (1) WO2022203552A1 (es)
ZA (1) ZA202309495B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005206277B2 (en) * 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
ES2961381T3 (es) * 2010-06-19 2024-03-11 Memorial Sloan Kettering Cancer Center Anticuerpos anti-GD2
US10167341B2 (en) * 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies

Also Published As

Publication number Publication date
ZA202309495B (en) 2026-02-25
ECSP23072412A (es) 2023-10-31
WO2022203552A1 (en) 2022-09-29
UY39687A (es) 2022-08-31
CO2023012549A2 (es) 2023-10-09
CN117677695A (zh) 2024-03-08
MX2023011246A (es) 2023-10-30
JOP20230231A1 (ar) 2023-09-24
TW202304989A (zh) 2023-02-01
MA62715A1 (fr) 2024-07-31
AR125219A1 (es) 2023-06-28
PY2221503A (es) 2022-09-29
PE20231854A1 (es) 2023-11-21
MA62715B1 (fr) 2025-01-31
CL2023002843A1 (es) 2024-03-22

Similar Documents

Publication Publication Date Title
PY24114686A (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente al ligando 1A (TL1A) similar al TNF, y uso del mismo
AR127635A1 (es) ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ra, Y USO DEL MISMO
CO2023012549A2 (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo
AR132867A1 (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a axl, y uso del mismo
AR129553A1 (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente a bcma, y uso del mismo
PY2530271A (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a bdca-2, y uso del mismo
CO2026005258A2 (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente al segmento trbv5-1 del dominio variable de la cadena beta del receptor de células t humano, y uso del mismo
AR132099A1 (es) Anticuerpo biespecífico aislado que se une específicamente al cd3 y al antígeno tumoral, y uso del mismo
CL2023003854A1 (es) Anticuerpo biespecífico aislado que se une específicamente a cd47 y pd-l1
AR105739A1 (es) Anticuerpos inhibidores de vía del factor tisular y usos de los mismos